Who we are
GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm’s innovative therapeutic approach is to target glial cells, the ‘support cells’ of neurons, to sustain their function and survival, and enhance brain metabolism in pathological conditions. We aim at developing new drugs that target glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.Don’t miss our latest news
GliaPharm is a Swiss biotechnology company that develops innovative approaches to treat neurological and psychiatric disorders by targeting glial cells in the brain, a type of cell that is critical for neuroprotection and brain metabolism.
GliaPharm was created in 2016 as a spinoff company of three decades of research performed in the laboratory of Prof. Pierre Magistretti at Ecole Polytechnique Fédérale de Lausanne (EPFL, Switzerland), a leading research laboratory in the field of brain metabolism and glial cell biology.
In 2017, GliaPharm has established its laboratory at the Campus Biotech in Geneva, Switzerland.
Through its in-house R&D laboratory and network with selective partners, GliaPharm provides the necessary platform to develop clinical applications through mode of actions targeting glial cells.